ASLAN Pharmaceuticals Initiates Phase IIb Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis

ASLAN Pharmaceuticals announced that it has screened the first patient in its Phase IIb dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis.